CTIS2023-503495-24-00招募中1 期
AMX-500-001
Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 271 人开始时间: 2023年7月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 271
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with pembrolizumab in patients with advanced solid tumorsSelected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).CTIS2024-514746-36-00Oncomatryx Biopharma S.L.120
进行中（未招募）
1 期
A study to investigate VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2024-514339-87-00VarmX B.V.12
招募中
1 期
A study to assess the safety, tolerability, uptake and efficacy of VMX-C001 in healthy volunteers.To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.MedDRA version: 20.0Level: PTClassification code: 10009773Term: Coagulation factor X level Class: 100000004848CTIS2023-507059-32-00VarmX B.V.48
招募中
1 期
Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients with Advanced Solid TumorsAdvanced Solid TumorsCTIS2024-513056-15-00Pharma Mar S.A.30
进行中（未招募）
1 期
A trial to investigate the effect of acalabrutinib on skin prick test wheal size in adults with grass pollen allergyCTIS2023-505783-11-00Alk-Abello A/S12